Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies

被引:518
作者
Brausi, M
Collette, L
Kurth, K
van der Meijden, AP
Oosterlinck, W
Witjes, JA
Newling, D
Bouffioux, C
Sylvester, RJ
机构
[1] European Org Res Treatment Canc, Eortc Data Ctr, B-1200 Brussels, Belgium
[2] Inst Sant Agostino, Modena, Italy
[3] Acad Med Centrum, NL-1005 AZ Amsterdam, Netherlands
[4] Jeroen Bosch Hosp, Shertogenbosch, Netherlands
[5] Univ Ziekenhuis Gent, B-9000 Ghent, Belgium
[6] Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
[7] Vrije Univ Amsterdam, Acad Ziekenhuis, Amsterdam, Netherlands
[8] Domaine Univ Sart Tilman, Ctr Hosp Univ Sart Tilman, Liege, Belgium
关键词
superficial bladder cancer; recurrence; cystoscopy; quality control; transurethral resection;
D O I
10.1016/S0302-2838(02)00068-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To assess the variability between institutions in the recurrence rate at the first follow-up cystoscopy (RR-FFC) after transurethral resection (TUR) in patients with stage Ta T I bladder cancer. Methods: A total of 2410 patients from seven EORTC phase III trials conducted between 1979 and 1989 were included. Patients with single and with multiple tumors were analyzed separately according to whether or not they received adjuvant intravesical treatment. Results: The RR-FFC varied greatly between institutions. For patients with a single tumor, it ranged from 3.4% to 20.6% for patients not receiving any intravesical adjuvant treatment and from 0% to 15.4% in those receiving it. In patients with multiple tumors who had adjuvant treatment, it varied between 7.4% and 45.8%. There was a slight decrease over time in the recurrence rate for patients with single tumors, particularly in those receiving adjuvant intravesical treatment. Conclusions: For both patients with single and with multiple tumors, the percentage of patients with a recurrence in the bladder at the first follow-up cystoscopy after TUR varies substantially between institutions and cannot be explained by the factors that were assessed. It is suggested that the quality of the TUR performed by the individual surgeons may be responsible. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:523 / 530
页数:8
相关论文
共 24 条
[1]   INTRAVESICAL ADJUVANT CHEMOTHERAPY FOR SUPERFICIAL TRANSITIONAL-CELL BLADDER-CARCINOMA - RESULTS OF 2 EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER RANDOMIZED TRIALS WITH MITOMYCIN-C AND DOXORUBICIN COMPARING EARLY VERSUS DELAYED INSTILLATIONS AND SHORT-TERM VERSUS LONG-TERM TREATMENT [J].
BOUFFIOUX, C ;
KURTH, KH ;
BONO, A ;
OOSTERLINCK, W ;
KRUGER, CB ;
DEPAUW, M ;
SYLVESTER, R ;
DENIS, L ;
NEWLING, D ;
HALL, R ;
BRESSEL, M ;
CASSELMAN, J ;
SMITH, P ;
ROBINSON, M ;
KEUPPENS, F ;
TOLLEY, D ;
JAKSE, G ;
BOLLACK, C ;
VERGISON, B ;
HOEKSTRA, W ;
DASILVA, FC ;
GROEN, J ;
RICHARDS, B ;
PAVONEMACALUSO, M ;
VANDERMEIJDEN, A ;
ZWARTENDIJK, H ;
JACOBI, G ;
VANCAUBERG, R ;
SCHRODER, F ;
HIRDES, D ;
LEISINGER, H ;
RIEDL, H ;
LUDWIG, P ;
ROOZENDAAL, K ;
MARECHAL, L ;
VANAUBEL, O ;
CONSIDINE, J ;
DEBRUYNE, F ;
CARREIRA, F ;
DEWALL, D ;
MENSINK, H ;
VIGGIANO, G .
JOURNAL OF UROLOGY, 1995, 153 (03) :934-941
[2]   ADJUVANT CHEMOTHERAPY OF RECURRENT SUPERFICIAL TRANSITIONAL CELL-CARCINOMA - RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER RANDOMIZED TRIAL COMPARING INTRAVESICAL INSTILLATION OF THIOTEPA, DOXORUBICIN AND CISPLATIN [J].
BOUFFIOUX, C ;
DENIS, L ;
OOSTERLINCK, W ;
VIGGIANO, G ;
VERGISON, B ;
KEUPPENS, F ;
DEPAUW, M ;
SYLVESTER, R ;
CHEUVART, B .
JOURNAL OF UROLOGY, 1992, 148 (02) :297-301
[3]   SINGLE DOSE INTRAVESICAL THIOTEPA AS AN ADJUVANT TO CYSTODIATHERMY IN TREATMENT OF TRANSITIONAL CELL BLADDER CARCINOMA [J].
BURNAND, KG ;
BOYD, PJR ;
MAYO, ME ;
SHUTTLEWORTH, KED ;
LLOYDDAVIES, RW .
BRITISH JOURNAL OF UROLOGY, 1976, 48 (01) :55-59
[4]  
Collette L, 1998, J UROLOGY, V159, P142
[5]  
GAVRELL GJ, 1978, J UROLOGY, V120, P410, DOI 10.1016/S0022-5347(17)57202-X
[6]   RESIDUAL TUMOR DISCOVERED IN ROUTINE 2ND TRANSURETHRAL RESECTION IN PATIENTS WITH STAGE-T1 TRANSITIONAL CELL-CARCINOMA OF THE BLADDER [J].
KLAN, R ;
LOY, V ;
HULAND, H .
JOURNAL OF UROLOGY, 1991, 146 (02) :316-318
[7]   HISTOPATHOLOGICAL SELF-CONTROL IN TRANSURETHRAL RESECTION OF BLADDER-TUMORS [J].
KOLOZSY, Z .
BRITISH JOURNAL OF UROLOGY, 1991, 67 (02) :162-164
[8]   Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone [J].
Kurth, K ;
Tunn, U ;
Ay, R ;
Schroder, FH ;
PavoneMacaluso, M ;
Debruyne, F ;
TenKate, F ;
DePauw, M ;
Sylvester, R ;
Essed, E ;
Caubergh, RV ;
Hoekstra, JW ;
deVoogt, HJ ;
Newling, DWW ;
deReijke, TM ;
Mensink, HJA ;
Groen, JM ;
Jakse, G ;
Leisinger, HJ ;
Richards, B ;
Adib, RA ;
Robinson, M ;
Denis, L ;
Bouffioux, C ;
Schulman, C ;
Carpentier, PJ .
JOURNAL OF UROLOGY, 1997, 158 (02) :378-384
[9]   FACTORS AFFECTING RECURRENCE AND PROGRESSION IN SUPERFICIAL BLADDER-TUMORS [J].
KURTH, KH ;
DENIS, L ;
BOUFFIOUX, C ;
SYLVESTER, R ;
DEBRUYNE, FMJ ;
PAVONEMACALUSO, M ;
OOSTERLINCK, W .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (11) :1840-1846
[10]  
Kurth KH, 1997, SUPERFICIAL BLADDER, P42